The Clinical Sciences certificate program is designed to enable those playing critical roles in the biopharmaceutical development process gain a thorough understanding of relevant regulations and guidelines, as well as a practical, real-world approach to conducting safer and more efficient clinical trials.
This educational track is designed for clinical professionals working as:
- Clinical Research Assistants and Associates
- Clinical Trial Managers
- Clinical Specialists and Investigators
- Drug Safety Specialists
- Epidemiologists
- Medical Affairs Professionals
- Medical Research Assistants and Associates
- Pharmacologists
- Principal Investigators
- Project Managers
- Study Coordinators
To earn the certificate, you must complete THREE core courses and ONE elective course from the list below. Courses must be completed within five years to remain eligible for earning a PERI certificate. Once you have completed the required courses, contact the PERI Registrar for validation, and the Clinical Sciences certificate will be mailed to you. If you have questions about your progress, contact PERI at info@peri.org.
Core Courses
In a blending of online and live learning, this course provides an overview of the process and issues common to all new chemical entity (NCE) development projects, from the research and development stages through product launch and post-marketing safety.
*NOTE: Students may only count Basic Drug Development or Decision Points in Pharmaceutical Development as one of the required core courses.
This fundamental online blended program pairs the essential Pharmacology Online distance education program with weekly webinars, case studies and online discussions to enhance learning and retention of key basic research information.
Related Course: Pharmacology Online Distance Education Program
Gain a broad multidisciplinary understanding of the scientific, management and regulatory decision points in the development of new biologics and biosimilars.
Gain a broad multidisciplinary understanding of the scientific, management and regulatory decision points in the development of new biologics and biosimilars.
This course focuses on global regulatory requirements required for the management of product safety data from clinical trial and post-market sources.
This course provides a detailed review of the legal and regulatory principles driving prescription drug labeling and patient labeling in the US, Canada and the EU.
This online course will provide you with a background in Good Clinical Practices (GCPs) as applied to clinical trials currently conducted worldwide.
The goal of this online course is to provide a practical orientation to site management and monitoring of clinical studies.
This introductory web-based module focuses on the critical decisions that are made throughout the development of a new chemical entity as the process evolves from discovery to first in humans and ultimately to launch.
Course recently revised and refreshed!
*NOTE: Students may only count Basic Drug Development or Decision Points in Pharmaceutical Development as one of the required core courses.
This virtual series is different from many other courses in that its perspective is from that of the site based investigator rather than the sponsor. All three courses must be completed in the series for credit.
This online course provides an intensive overview of pharmacology, knowledge of which is critical for both drug discovery and development.
Course recently revised and refreshed!
This online course reviews statistical terminology, provide an understanding of statistics, and explain trial design from a clinician’s viewpoint.
Course recently revised and refreshed!
Elective Courses
This course provides an overview of human cancer with discussions on specific cancer types, current therapeutics and clinical trial design.
View the Open Course Schedule for Upcoming Programs
This course provides a comprehensive overview of US, European, Canadian, Japanese and Rest-of-World (ROW)/ Emerging Market regulations for drug and biologic development from pre-clinical to post approval.
This course addresses clinical trial management issues and skills needed to effectively conduct trials in the fast-paced drug development industry.
This course covers oncologic clinical trials from Phase I through Phase III with discussions of relevant design, ethical and regulatory issues, as well results of complex trials.
This course provides an intuitive approach to pharmacokinetic (PK) concepts, using easily understood mathematical and descriptive teaching methods.
Related Course: Pharmacology Online Distance Education Program
This course addresses project management issues and skills needed to wisely choose and effectively develop new therapies in today’s global climate.
This course presents industry and FDA experts on current issues regarding FDA regulation of promotional activities such as direct-to-consumer advertising, social media, scientific exhibits, off-label communications as well as trends in FDA enforcement.
Continuing Education Credits
Pharmaceutical Education & Research Institute, Inc. (PERI) is pleased to make continuing education credit available to you for attendance at this program. To receive credit, you must attend the entire program and submit the Continuing Education Application form directly to a PERI on-site coordinator. Additional $35 fee applies for students who are applying for continuing education credit.
Continuing Medical Education (CME)
PERI, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education (CPE)
Pharmaceutical Education & Research Institute, Inc. (PERI) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an application-based CPE Activity.
Ready to Start?
Apply in just two minutes or start searching for courses immediately.
Current Students: Track Progress
Submit your basic contact information to receive a progress update report.